NIH R01 · 2025
Protocol Synopsis-Brief Summary Study Overview. We will enroll Breast Cancer Survivors (BCS) who completed initial treatment within 3 – 12 months which may or may not have included chemotherapy, are continuing on adjuvant endocrine therapy (AET), who are distressed, mid-older aged (> 50yrs), post- menopausal, and were diagnosed with Stage I – III HR+ (ER/PR+), Her2neu- breast cancer. We will have a brief run-in period starting just after treatment completion (i.e., waiting period prior to randomization) where potentially eligible participants will undergo screening. At least 3 months and up to 12 months after the completion of initial treatment they will be asked to complete a baseline…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.